The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Tofacitinib After Live Shingles Vaccination Does Not Impair Immunogenicity

Tofacitinib After Live Shingles Vaccination Does Not Impair Immunogenicity

August 29, 2017 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Tofacitinib begun two to three weeks after live zoster vaccination does not impair immunogenicity, and vaccination appears to be safe in patients with pre-existing varicella zoster virus (VZV) immunity, researchers report.

You Might Also Like
  • The Effect of Tofacitinib on Live Vaccine Responses
  • Herpes Zoster & Tofacitinib
  • Shingles Vaccination Not at Goal Levels for U.S. Seniors

Patients with rheumatoid arthritis (RA) are about twice as likely as healthy adults to develop herpes zoster, or shingles, and the risk is even higher with some disease-modifying antirheumatic drugs, including tofacitinib.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Kevin L. Winthrop from Oregon Health and Science University, in Portland, and colleagues investigated the safety and immunogenicity of live zoster vaccination in their Phase 2 study of 112 patients with active RA on stable background methotrexate therapy.

Patients were randomized to receive 5 mg tofacitinib twice daily or placebo beginning two to three weeks after receiving live zoster vaccine.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Among the 107 patients evaluable for immune response endpoints, the geometric mean fold rise (GMFR) in VZV-specific immunoglobulin G (IgG) six weeks post-vaccination (the primary endpoint) did not differ significantly between the tofacitinib (2.11) and placebo (1.74) groups, according to the Aug. 24 Arthritis & Rheumatology online report.1

At all post-vaccination time points, GMFR in VZV-specific IgG tended to be numerically higher in tofacitinib recipients, but the differences were small and not statistically significant.

VZV-specific interferon-gamma-secreting T-cell counts and GMFR also were similar between the tofacitinib and placebo groups.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

One patient in the tofacitinib group developed disseminated primary varicella with the vaccine strain of VZV, and subsequent analysis of her baseline blood specimens showed that she lacked pre-existing immunity to VZV. She subsequently developed robust immunity to VZV.

“We observed that patients with active RA developed robust immune responses to this vaccine, and that the start of tofacitinib two to three weeks after vaccination had no negative impact on the established immune response,” the researchers note.

“Importantly,” they add,” while our results suggest that the vaccine is safe for patients with RA with prior VZV exposure, they also indicate the potential need to either screen for prior exposure before giving this vaccine or waiting longer than two to three weeks before starting immunosuppression with tofacitinib.”

Pfizer Inc. sponsored the study, employed 8 of the 11 authors, and had various relationships with the other three.

Dr. Winthrop did not respond to a request for comment.


Reference

  1. Winthrop KL, Wouters A, Choy E, et al. The safety and immunogenicity of live zoster vaccination in rheumatoid arthritis patients before starting tofacitinib: A randomized phase 2 trial. Arthritis Rheumatol. 2017 Aug 28. doi: 10.1002/art.40187. [Epub ahead of print]

Pages: 1 2 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: Arthritis & Rheumatology, shingles, Tofacitinib, vaccine, varicella zoster virus

You Might Also Like:
  • The Effect of Tofacitinib on Live Vaccine Responses
  • Herpes Zoster & Tofacitinib
  • Shingles Vaccination Not at Goal Levels for U.S. Seniors
  • Shingles, Chickenpox Hospitalizations Higher for Patients on Anti-TNF Drugs

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)